Konekti, is the first global Healthcare “curated” network
that connects physicians with their Associations and Pharmas. Simple. Intuitive. Scalable.
For Healthcare professionals Konekti provides:
i. Single point of communication with Associations & Pharma’s
ii. Access to updated research, CME, protocols, publications and latest clinical trials
iii. Keep practice up-to-date with latest technology.
The Associations will be able to:
i. Manage and engage their professional member base
ii. Is a single point of communication with them
iii. Run real time research with their affiliates
iv. Receive instant feedback to content, news and updates
Pharma companies will be able to:
i. Access validated and active Healthcare professionals networks
ii. Single point of communication with them
iii. Receive real time response to promotions, detailing and activities
iv. Engaged the audience with their portfolio of products as well as content
v. Cost efficient traceable tool
vi. Pharmacovigilance validated
Konekti solves Pharma critical “pain-points” in an efficient and relevant way:
1 - CUSTOMER ACQUISITION:
By leveraging existing databases of Healthcare professionals from Medical Societies and Associations. databases are current and validated. Professionals approve agreement to terms and conditions when installing Konekti.
2 - CUSTOMER VALIDATION:
Medical Associations certify that their databases are comprised exclusively by active Healthcare professionals.
3 - CUSTOMER ENGAGEMENT:
With simple access to industries’ updates of products, clinical trials, publications, etc our non-intrusive mobile technology allows Healthcare professionals to control the flow of information and engage with their interests.
4 - PHARMACOVIGILANCE REQUIREMENTS:
In compliance with Pharmacovigilance legislation our two way communication is pre-formatted (no open text), selected and curated by the Associations creating a controlled environment where Pharma companies can interact with Healthcare professionals. Additionally our ‘Report an Issue Tool’ allows physicians to report potential pharmacovigilance cases directly to the Pharma Companies.